301 related articles for article (PubMed ID: 26435212)
1. Apolipoprotein C-III: From Pathophysiology to Pharmacology.
Norata GD; Tsimikas S; Pirillo A; Catapano AL
Trends Pharmacol Sci; 2015 Oct; 36(10):675-687. PubMed ID: 26435212
[TBL] [Abstract][Full Text] [Related]
2. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
[TBL] [Abstract][Full Text] [Related]
3. [Mutations of APOC3 gene, metabolism of triglycerides and reduction of ischemic cardiovascular events].
Pirillo A; Catapano AL
G Ital Cardiol (Rome); 2015 May; 16(5):289-94. PubMed ID: 25994465
[TBL] [Abstract][Full Text] [Related]
4. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
5. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.
Packard CJ; Pirillo A; Tsimikas S; Ference BA; Catapano AL
Cardiovasc Res; 2024 Feb; 119(18):2843-2857. PubMed ID: 38039351
[TBL] [Abstract][Full Text] [Related]
6. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
7. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease.
Silbernagel G; Scharnagl H; Kleber ME; Hoffmann MM; Delgado G; Stojakovic T; Gary T; Zeng L; Ritsch A; Zewinger S; Speer T; Schunkert H; Landmesser U; März W; Grammer TB
Atherosclerosis; 2020 Oct; 311():84-90. PubMed ID: 32949947
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
9. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
10. Targeting ApoC-III to Reduce Coronary Disease Risk.
Khetarpal SA; Qamar A; Millar JS; Rader DJ
Curr Atheroscler Rep; 2016 Sep; 18(9):54. PubMed ID: 27443326
[TBL] [Abstract][Full Text] [Related]
11. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
[TBL] [Abstract][Full Text] [Related]
12. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.
Taskinen MR; Björnson E; Matikainen N; Söderlund S; Rämö J; Ainola MM; Hakkarainen A; Sihlbom C; Thorsell A; Andersson L; Bergh PO; Henricsson M; Romeo S; Adiels M; Ripatti S; Laakso M; Packard CJ; Borén J
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040803
[TBL] [Abstract][Full Text] [Related]
13. APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups.
Goyal S; Tanigawa Y; Zhang W; Chai JF; Almeida M; Sim X; Lerner M; Chainakul J; Ramiu JG; Seraphin C; Apple B; Vaughan A; Muniu J; Peralta J; Lehman DM; Ralhan S; Wander GS; Singh JR; Mehra NK; Sidorov E; Peyton MD; Blackett PR; Curran JE; Tai ES; van Dam R; Cheng CY; Duggirala R; Blangero J; Chambers JC; Sabanayagam C; Kooner JS; Rivas MA; Aston CE; Sanghera DK
Lipids Health Dis; 2021 Sep; 20(1):113. PubMed ID: 34548093
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
Spagnuolo CM; Hegele RA
Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.
Jong MC; Rensen PC; Dahlmans VE; van der Boom H; van Berkel TJ; Havekes LM
J Lipid Res; 2001 Oct; 42(10):1578-85. PubMed ID: 11590213
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.
Larsson M; Allan CM; Jung RS; Heizer PJ; Beigneux AP; Young SG; Fong LG
J Lipid Res; 2017 Sep; 58(9):1893-1902. PubMed ID: 28694296
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein C-II: the re-emergence of a forgotten factor.
Wolska A; Reimund M; Remaley AT
Curr Opin Lipidol; 2020 Jun; 31(3):147-153. PubMed ID: 32332429
[TBL] [Abstract][Full Text] [Related]
19. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
[TBL] [Abstract][Full Text] [Related]
20. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
Yang X; Lee SR; Choi YS; Alexander VJ; Digenio A; Yang Q; Miller YI; Witztum JL; Tsimikas S
J Lipid Res; 2016 Apr; 57(4):706-13. PubMed ID: 26848137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]